FDA clos­es out se­ries of pa­tient-fo­cused drug de­vel­op­ment guid­ance

The FDA on Wednes­day re­leased its fourth (of four) pa­tient-fo­cused drug de­vel­op­ment guid­ance doc­u­ments, with this lat­est draft fea­tur­ing long-await­ed ad­vice on how to col­lect and sub­mit da­ta on the in­di­vid­ual ex­pe­ri­ences of pa­tients to in­form reg­u­la­to­ry de­ci­sions.

So-called clin­i­cal out­come as­sess­ment (COA)-based end­points fea­ture promi­nent­ly in the draft, with the FDA say­ing COAs are “in­tend­ed to re­flect, di­rect­ly or in­di­rect­ly, how pa­tients feel, func­tion, or sur­vive.” But there are lots of dos and don’ts when it comes to COAs, and spon­sors may fre­quent­ly en­counter chal­lenges, many of which are out­lined in the 45-page draft.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER